Author: Zhang, L.; Zheng, X.; Bai, X.; Wang, Q.; Chen, B.; Wang, H.; Lu, J.; Hu, S.; Zhang, X.; Zhang, H.; Liu, J.; Shi, Y.; Zhou, Z.; Gan, L.; Li, X.; Li, J.
Title: Association between Use of Qingfei Paidu Tang and Mortality in Hospitalized Patients with COVID-19: A national retrospective registry study Cord-id: y1jl2fcm Document date: 2020_12_26
ID: y1jl2fcm
Snippet: Background Qingfei Paidu Tang (QPT), a formula of traditional Chinese medicine, which was suggested to be able to ease symptoms in patients with Coronavirus Disease 2019 (COVID-19), has been recommended by clinical guidelines and widely used to treat COVID-19 in China. However, whether it decreases mortality remains unknown. Purpose We aimed to explore the association between QPT use and in-hospital mortality among patients hospitalized for COVID-19. Study design A retrospective study based on a
Document: Background Qingfei Paidu Tang (QPT), a formula of traditional Chinese medicine, which was suggested to be able to ease symptoms in patients with Coronavirus Disease 2019 (COVID-19), has been recommended by clinical guidelines and widely used to treat COVID-19 in China. However, whether it decreases mortality remains unknown. Purpose We aimed to explore the association between QPT use and in-hospital mortality among patients hospitalized for COVID-19. Study design A retrospective study based on a real-world database was conducted. Methods We identified patients consecutively hospitalized with COVID-19 in 15 hospitals from a national retrospective registry in China, from January through May 2020. Data on patients' characteristics, treatments, and outcomes were extracted from the electronic medical records. The association of QPT use with mortality was evaluated using Cox proportional hazards models based on propensity score analysis. Results Of the 8939 patients included, 28.7% received QPT. The crude mortality was 1.2% (95% confidence interval [CI] 0.8% to 1.7%) among the patients receiving QPT and 4.8% (95% CI 4.3% to 5.3%) among those not receiving QPT. After adjustment for patient characteristics and concomitant treatments, QPT use was associated with a relative reduction of 50% in in-hospital mortality (hazard ratio, 0.50; 95% CI, 0.37 to 0.66 P <0.001). This association was consistent across subgroups by sex and age. Meanwhile, the incidence of acute liver injury (8.9% [95% CI, 7.8% to 10.1%]vs. 9.9% [95% CI, 9.2% to 10.7%]; odds ratio, 0.96 [95% CI, 0.81% to 1.14%], P =0.658) and acute kidney injury (1.6% [95% CI, 1.2% to 2.2%] vs. 3.0% [95% CI, 2.6% to 3.5%]; odds ratio, 0.85 [95% CI, 0.62 to 1.17], P =0.318) was comparable between patients receiving QPT and those not receiving QPT. The major study limitations included that the study was an observational study based on real-world data rather than a randomized control trial, and the quality of data could be affected by the accuracy and completeness of medical records. Conclusions QPT was associated with a substantially lower risk of in-hospital mortality, without extra risk of acute liver injury or acute kidney injury among patients hospitalized with COVID-19. Key words Qingfei Paidu Tang; Mortality; COVID-19 Abbreviations QPT: Qingfei Paidu Tang COVID-19: Coronavirus Disease 2019 IQR: interquartile range SMD: standard mean difference IPTW: inverse probability treatment weighting HR: hazard ratios OR: odds ratios CI: confidence interval
Search related documents:
Co phrase search for related documents- acute kidney injury and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date